
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals Inc. has demonstrated a strong growth trajectory, evidenced by a projected increase in adjusted operating margin from 25.4% in 2024 to 29.7% by 2028, alongside expected operating cash flow exceeding $630 million from 2025 to 2028. Continued demand in the ACTH gel market and successful launches of products like Prucalopride contribute positively to revenue growth, with FY 2025 revenue estimates raised to $269.5 million, reflecting ongoing strength in the company's brand and generic portfolios. Additionally, the avoidance of competitive pressures from potential acquisitions of Mallinckrodt has helped stabilize pricing, bolstering the company’s market position in the orphan drug segment.
Bears say
ANI Pharmaceuticals has experienced a notable decline in revenue within its Brands segment during the second and third quarters of 2024, attributed to unfavorable market conditions affecting certain molecules. Additionally, the company has faced persistent pricing pressures, particularly with Cortrophin, as evidenced by revenue decreases of 12% and 10% in the first quarters of 2023 and 2024, respectively, raising concerns over its future performance. Furthermore, projected revenue for 1Q 2025 is expected to dip significantly over 30% due to seasonal factors and complications related to Medicare access issues, which could adversely impact overall financial stability.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares